Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CASTEMI: Caldaret in STEMI Patients Undergoing PCI
NCT00078013Phase 2
Key facts
- Status
- Completed
- Start
- Apr 2003
- Countries
- 1
- Modality
- Small Molecules
- Drugs
- Caldaret
- Conditions
- ST elevation myocardial infarction (STEMI)
01
Overview
Phase 2, randomised, double-blind trial of Caldaret in ST elevation myocardial infarction (STEMI) (3 arms), sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoints: Final infarct size measured by single photon emission computed tomography (SPECT) at Day 180, Safety at Day 180 and 1 more. Started Apr 2003; status: completed.
02
Design
3 arms- Study design
- RandomizedDouble-blind
Group A
MCC-135 4.5 mg/kg/48 hours
Group B
MCC-135 9.0 mg/kg/48 hours
Group C
Placebo/48 hours
03
Endpoints
Primary
Final infarct size measured by single photon emission computed tomography (SPECT)
Safety
Tolerability
Beyond the preview
Go deeper on NCT00078013.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00078013.